atrasentan has been researched along with bilirubin in 1 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (bilirubin) | Trials (bilirubin) | Recent Studies (post-2010) (bilirubin) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 25,921 | 1,337 | 5,871 |
| Protein | Taxonomy | atrasentan (IC50) | bilirubin (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 3.3884 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.3183 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; Davis, JW; de Zeeuw, D; Heerspink, HJ; Idler, K; Kohan, DE; Liu, M; Makino, H; Parving, HH; Perkovic, V; Remuzzi, G; Tobe, SW; Toto, R | 1 |
1 trial(s) available for atrasentan and bilirubin
| Article | Year |
|---|---|
Comparison of exposure response relationship of atrasentan between North American and Asian populations.
Topics: Aged; Albuminuria; Asia; Asian People; Atrasentan; Bilirubin; Body Fluids; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; North America; Pyrrolidines; Treatment Outcome; Weight Gain; White People | 2017 |